This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB08959/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/drug/DB08959/identifier/drugbank/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB08959
rdf:type
n3:Drug
n3:description
A synthetic estrogen that has been used as a hormonal antineoplastic agent.
n3:generalReferences
# Liehr JG, Ballatore AM, Dague BB, Ulubelen AA: Carcinogenicity and metabolic activation of hexestrol. Chem Biol Interact. 1985 Oct;55(1-2):157-76. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2998630
n3:group
withdrawn
owl:sameAs
n10:DB08959
dcterms:title
Hexestrol
adms:identifier
n6:DB08959 n7:D07826
n3:synonym
Hexanoestrol Synoestrolum Hexoestrolum
n3:salt
n3:synthesisReference
U.S. Patent 2,357,985; U.S. Patent 2,421,401.
n3:IUPAC-Name
n4:271B6015-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B601B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B601A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6017-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6018-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6019-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6013-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6011-363D-11E5-9242-09173F13E4C5 n4:271B6014-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6012-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6021-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6022-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B601C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B601D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B601F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B601E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6020-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
84-16-2
n3:Bioavailability
n4:271B6027-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6029-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B602A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B602B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6026-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6025-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6028-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6016-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6023-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6024-363D-11E5-9242-09173F13E4C5